The National ALS Clinical and Research Group undertakes research in epidemiology, cognition, genetics, bioinformatics, drug development and novel biomarker development, and commercial and investigator led clinical trials of novel compounds in ALS. Much of our clinical research is supported by the charity Research Motor Neurone.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.